MA51658A - Association comprenant un antagoniste de nk1 et méthode de traitement de synucléinopathies - Google Patents

Association comprenant un antagoniste de nk1 et méthode de traitement de synucléinopathies

Info

Publication number
MA51658A
MA51658A MA051658A MA51658A MA51658A MA 51658 A MA51658 A MA 51658A MA 051658 A MA051658 A MA 051658A MA 51658 A MA51658 A MA 51658A MA 51658 A MA51658 A MA 51658A
Authority
MA
Morocco
Prior art keywords
synucleinopathies
antagonist
treatment
association including
association
Prior art date
Application number
MA051658A
Other languages
English (en)
Inventor
Thomas N Chase
Kathleen E Clarence-Smith
Original Assignee
Chase Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chase Therapeutics Corp filed Critical Chase Therapeutics Corp
Publication of MA51658A publication Critical patent/MA51658A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA051658A 2017-04-10 2018-04-09 Association comprenant un antagoniste de nk1 et méthode de traitement de synucléinopathies MA51658A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762483555P 2017-04-10 2017-04-10

Publications (1)

Publication Number Publication Date
MA51658A true MA51658A (fr) 2020-12-02

Family

ID=63792736

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051658A MA51658A (fr) 2017-04-10 2018-04-09 Association comprenant un antagoniste de nk1 et méthode de traitement de synucléinopathies

Country Status (16)

Country Link
US (1) US11160809B2 (fr)
EP (2) EP4461362A3 (fr)
JP (1) JP7271437B2 (fr)
KR (1) KR20200002899A (fr)
CN (1) CN110730662A (fr)
AU (1) AU2018251604B2 (fr)
BR (1) BR112019021125A2 (fr)
CA (1) CA3059418A1 (fr)
EA (1) EA201992414A1 (fr)
ES (1) ES2986644T3 (fr)
HU (1) HUE068710T2 (fr)
IL (3) IL312486B2 (fr)
MA (1) MA51658A (fr)
MX (1) MX394351B (fr)
TW (1) TWI803488B (fr)
WO (1) WO2018191160A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7158425B2 (ja) 2017-06-30 2022-10-21 チェイス セラピューティクス コーポレイション Nk-1アンタゴニスト組成物およびうつ病の処置における使用法
IL294408A (en) 2019-12-31 2022-08-01 Chase Therapeutics Corp Kinases as biomarkers for neurodegenerative conditions
WO2022182658A1 (fr) * 2021-02-23 2022-09-01 Hoth Therapeutics, Inc. Utilisation d'aprépitant pour le traitement de la maladie d'alzheimer

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572485D1 (en) 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
DE9290063U1 (de) 1991-05-31 1994-02-24 Pfizer Inc., New York, N.Y. Chinuclidin-Derivate
US5719147A (en) 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
EP0942732B1 (fr) 1996-12-02 2004-11-17 MERCK SHARP & DOHME LTD. Utilisation d'antagonistes du recepteur nk-1 dans le traitement des diskynesies
DE19830201A1 (de) 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
WO2000006162A1 (fr) * 1998-07-27 2000-02-10 Boehringer Ingelheim Pharma Kg Agents a effet antidepresseur, comprenant du pramipexol et un autre antidepresseur
DE60045564D1 (de) 1999-02-24 2011-03-03 Hoffmann La Roche 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
CA2415890C (fr) 2000-07-14 2009-04-07 F. Hoffmann-La Roche Ag N-oxydes en tant que promedicaments de derives de 4-phenyl-pyridine, antagonistes du recepteur nk1
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
DE60123661T2 (de) 2000-12-14 2007-08-16 F. Hoffmann-La Roche Ag Selbstemulgierende lipidmatrix (selm)
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
GB0310881D0 (en) * 2003-05-12 2003-06-18 Merck Sharp & Dohme Pharmaceutical formulation
AR047439A1 (es) 2004-01-27 2006-01-18 Merck & Co Inc Antagonistas del receptor hidroisoindolina taquiquinina
LT1713504T (lt) 2004-01-30 2017-09-11 Zoetis Services Llc Antimikrobinis konservantas, skirtas multi-dozinėms kompozicijoms, panaudojant beta-ciklodekstrinus, skirtas skystoms vaisto formoms
US20120253047A1 (en) 2004-03-19 2012-10-04 Dipharma S.P.A. Process for the preparation of (r)-pramipexole
WO2006094948A1 (fr) * 2005-03-08 2006-09-14 Janssen Pharmaceutica N.V. Dérivés de diaza-spiro-[4.4]-nonane en tant qu'antagonistes de neurokinines (nk1)
DE602006020450D1 (de) 2005-07-11 2011-04-14 Merck Sharp & Dohme Ykinin-rezeptorantagonisten
ES2334061T3 (es) 2005-08-15 2010-03-04 University Of Virginia Patent Foundation Neurorrestauracion con pramipexol r(+).
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
PL2026803T3 (pl) 2006-05-16 2012-05-31 Knopp Neurosciences Inc Kompozycje R(+) i S(-) pramipeksolu i sposoby ich zastosowania
CN101641096A (zh) * 2006-12-14 2010-02-03 诺普神经科学股份有限公司 (r)-普拉克索的组合物以及使用该组合物的方法
AU2008224869A1 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US20080254117A1 (en) 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
GB0806652D0 (en) 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
CN102573475B (zh) 2009-08-14 2016-01-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
EP2722045B1 (fr) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions pour traiter les nausées et vomissements à médiation centrale
WO2012140604A1 (fr) 2011-04-15 2012-10-18 Sandoz Ag Formulations stables de chlorhydrate de pramipexole
WO2012175434A1 (fr) 2011-06-20 2012-12-27 Glaxo Group Limited Formulations pharmaceutiques comprenant du vestipitant
ES2750246T3 (es) 2013-10-08 2020-03-25 Innopharma Inc Formulaciones liquidas orales de aprepitant
JP6741655B2 (ja) 2014-09-19 2020-08-19 ヘロン セラピューティクス, インコーポレイテッドHeron Therapeutics, Inc. アプレピタントのエマルジョン製剤
US9850267B2 (en) 2015-06-03 2017-12-26 Navinta, Llc Crystalline fosaprepitant dicyclohexylamine salt and its preparation
NL2015865B1 (en) 2015-11-27 2017-06-13 Le Vet B V Maropitant Formulation.
JP7158425B2 (ja) * 2017-06-30 2022-10-21 チェイス セラピューティクス コーポレイション Nk-1アンタゴニスト組成物およびうつ病の処置における使用法

Also Published As

Publication number Publication date
EP3609495C0 (fr) 2024-07-24
IL309770B1 (en) 2024-10-01
CA3059418A1 (fr) 2018-10-18
BR112019021125A2 (pt) 2020-05-12
IL269875B2 (en) 2024-06-01
IL312486B2 (en) 2025-05-01
IL309770A (en) 2024-02-01
CN110730662A (zh) 2020-01-24
WO2018191160A1 (fr) 2018-10-18
KR20200002899A (ko) 2020-01-08
IL269875A (fr) 2019-12-31
IL312486A (en) 2024-07-01
HUE068710T2 (hu) 2025-01-28
ES2986644T3 (es) 2024-11-12
AU2018251604B2 (en) 2022-04-14
IL269875B1 (en) 2024-02-01
EP3609495A4 (fr) 2020-12-02
AU2018251604A1 (en) 2019-11-21
IL312486B1 (en) 2025-01-01
JP2020516625A (ja) 2020-06-11
EA201992414A1 (ru) 2020-03-16
US11160809B2 (en) 2021-11-02
EP3609495A1 (fr) 2020-02-19
MX2019012088A (es) 2020-02-07
TW201841634A (zh) 2018-12-01
IL309770B2 (en) 2025-02-01
EP4461362A3 (fr) 2025-02-19
US20200147097A1 (en) 2020-05-14
TWI803488B (zh) 2023-06-01
EP3609495B1 (fr) 2024-07-24
EP4461362A2 (fr) 2024-11-13
MX394351B (es) 2025-03-24
JP7271437B2 (ja) 2023-05-11

Similar Documents

Publication Publication Date Title
EP3766431A4 (fr) Dispositif médical et méthode de traitement
EP3380121A4 (fr) Méthode de traitement de troubles oculaires
MA46098A (fr) Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r
EP3779023A4 (fr) Appareil de traitement de vêtements
EP3706737A4 (fr) Inhibiteurs de ash1l et méthodes de traitement comprenant ces derniers
EP3778649A4 (fr) Méthode et composition de traitement de tumeurs
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
EP3832007A4 (fr) Appareil de traitement de vêtements
EP3522934A4 (fr) Compositions et méthode pour le traitement de la rénopathie
EP3427678A4 (fr) Dispositif médical et méthode de traitement
EP3820461A4 (fr) Méthode de traitement du cancer
MA48730A (fr) Compositions et méthodes de traitement de synucléinopathies
EP3273955A4 (fr) Traitement de maladies respiratoires
EP3373962A4 (fr) Compositions et méthodes de traitement de maladies auto-immunes et de cancers
IL269363A (en) Methods for measuring therapeutic effects of retinal disease therapies
MA46061A (fr) Traitement ascaroside de maladies auto-immunes et inflammatoires
EA201791901A1 (ru) Антагонисты рецептора нейрокинина-3 для терапевтического или косметологического лечения излишних жировых отложений на теле
MA41462A (fr) Méthode de traitement de maladies
EP3331499A4 (fr) Composition et méthode de traitement de troubles métaboliques
EP3448365A4 (fr) Méthode de traitement de la constipation
EP3344258A4 (fr) Traitement de maladies auto-immunes et de maladies auto-inflammatoires
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
EP3933099A4 (fr) Appareil de traitement de vêtements
EP3976829A4 (fr) Méthode de traitement ou de prophylaxie
MA51658A (fr) Association comprenant un antagoniste de nk1 et méthode de traitement de synucléinopathies